Resmed
RMD
$200.29
+0.85%
ResMed Inc. is a global leader in the medical devices industry, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea and other respiratory conditions. The company is a dominant market player in the structurally growing sleep apnea market, distinguished by its integrated hardware and software solutions aimed at digital health and out-of-hospital care. The current investor narrative is shaped by strategic acquisitions to expand its therapy portfolio, such as the recent $340 million purchase of Noctrix Health, and debates around its growth trajectory amid competitive pressures and the integration of its digital health initiatives.…
RMD
Resmed
$200.29
Related headlines
Investment Opinion: Should I buy RMD Today?
Rating & Thesis: Hold. ResMed is a high-quality company caught in a significant downtrend; investors should wait for evidence of a fundamental or technical inflection before committing new capital, despite the attractive forward valuation. The mixed analyst sentiment and lack of a clear near-term catalyst support a neutral stance.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The forward P/E of 15.56x is compelling for a company with 23.47% ROE, but 2) revenue growth is decelerating (11% YoY), 3) the stock is in a severe technical downtrend (-25% Y/Y), and 4) analyst coverage is limited and mixed, offering no strong consensus tailwind. The stock trades at a premium to the sector on a trailing basis (P/E 27.02x) but a discount to its own historical peaks, creating valuation ambiguity.
Risks & Conditions: The two biggest risks are prolonged growth deceleration and further technical breakdown below the $180 support. This Hold would upgrade to a Buy if quarterly revenue growth re-accelerates above 13% YoY while gross margins hold above 62%, signaling the downtrend is overdone. It would downgrade to a Sell if the stock breaks decisively below its 52-week low ($180.27) on high volume, confirming the bear trend's continuation. Relative to its history and sector, the stock is in a state of transition from overvalued to fairly valued, but the process is not yet complete.
Sign up to view all
RMD 12-Month Price Forecast
ResMed presents a complex picture where deteriorating momentum conflicts with a still-strong underlying business. The neutral stance reflects the high probability (50%) of a base-case scenario where the stock treads water as growth stabilizes. The compelling forward valuation and stellar cash flow limit severe downside, but the lack of a visible growth re-acceleration catalyst caps near-term upside. Confidence is medium due to the limited analyst coverage, which adds uncertainty. The stance would turn bullish on confirmation of sustained double-digit revenue growth and a technical breakout above the $260 resistance level; it would turn bearish on a breakdown below $180 coupled with another quarter of sub-8% growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Resmed's 12-month outlook, with a consensus price target around $260.38 and implied upside of +30.0% versus the current price.
Average Target
$260.38
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$160 - $260
Analyst target range
Analyst coverage for ResMed is limited, with only 7 analysts providing estimates, indicating this is a stock with more focused institutional following rather than broad coverage. The consensus sentiment appears mixed, with recent institutional ratings including actions like 'Buy', 'Outperform', 'Equal Weight', 'Neutral', and 'Hold'. The average revenue estimate for the period is $7.70 billion, with a range from $7.63 billion to $7.78 billion, showing tight clustering and high conviction in the near-term revenue outlook. The limited number of covering analysts can lead to higher volatility and less efficient price discovery, as the stock may be more sensitive to individual rating changes and specific company news rather than a broad Wall Street consensus.
Bulls vs Bears: RMD Investment Factors
The investment debate for ResMed is a classic clash between deteriorating price momentum and enduring fundamental strength. The bear side currently presents stronger evidence, as the severe technical breakdown (-25% Y/Y) and decelerating revenue growth are immediate, observable realities. However, the bull case is underpinned by exceptionally strong profitability (28% net margin), a pristine balance sheet (D/E 0.14), and a forward P/E that prices in significant earnings growth. The single most important tension is whether the company's high-quality fundamentals and strategic positioning in a growing market can overcome the powerful negative technical trend and justify its still-premium trailing valuation. The resolution hinges on the next few quarters of revenue growth and margin performance.
Bullish
- Exceptional Profitability & Cash Flow: ResMed maintains superior profitability with a net margin of 27.59% and an operating margin of 34.97% in the latest quarter. The company generates robust free cash flow of $1.79 billion TTM, providing ample resources for strategic acquisitions and shareholder returns.
- Strong Balance Sheet & Low Financial Risk: The company has a fortress-like balance sheet with a debt-to-equity ratio of 0.14 and a current ratio of 3.44. This low leverage and high liquidity position RMD to weather economic downturns and fund growth without financial distress.
- Attractive Forward Valuation: The stock's forward P/E of 15.56x is significantly below its trailing P/E of 27.02x, reflecting market expectations for earnings growth. This forward multiple suggests the stock may be undervalued relative to its historical premium, especially given its high-quality fundamentals.
- Structural Market Growth & Strategic Acquisitions: ResMed operates in the structurally growing sleep apnea market. Recent strategic moves, like the $340 million acquisition of Noctrix Health, expand its therapy portfolio into adjacent areas like Restless Legs Syndrome, potentially opening new revenue streams.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is in a deep correction, down 24.81% over the past year and 22.99% over six months, significantly underperforming the S&P 500 by nearly 50%. Trading near its 52-week low of $180.27, the price action signals persistent and accelerating selling pressure.
- Revenue Growth Deceleration: While still positive, quarterly revenue growth has decelerated to 10.98% YoY. This slowdown from higher historical rates raises concerns about the company's ability to maintain its premium valuation in the face of competitive pressures.
- Premium Trailing Valuation vs. Sector: Despite the price decline, RMD's trailing P/E of 27.02x trades at a premium to the broader sector. This premium leaves the stock vulnerable to further multiple compression if growth continues to moderate or if investor sentiment sours on healthcare equipment.
- Limited Analyst Coverage & Sentiment Risk: With only 7 covering analysts, price discovery is less efficient and the stock is more susceptible to volatility from individual rating changes. The mixed institutional ratings (including Holds and Neutrals) reflect uncertainty about the near-term catalyst path.
RMD Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -24.81% and a 6-month decline of -22.99%, significantly underperforming the broader market. As of the latest close of $188.63, the price is trading near the lower end of its 52-week range, positioned at approximately 9% above its 52-week low of $180.27 and 36% below its high of $293.81, indicating the stock is in a deep correction and may be approaching oversold territory. Recent momentum remains negative, with a 1-month decline of -9.22% and a 3-month drop of -16.53%, confirming the bearish trend is accelerating in the short term. This persistent weakness is underscored by a relative strength reading of -49.80% versus the S&P 500 over the past year, highlighting severe underperformance. Key technical levels are clear, with immediate support at the 52-week low of $180.27 and major resistance at the 52-week high of $293.81. A breakdown below support could signal further downside, while a recovery would need to overcome significant overhead supply. The stock's beta of 0.78 indicates it has been less volatile than the market during this decline, which may offer some relative stability but does not negate the strong negative price action.
Beta
0.78
0.78x market volatility
Max Drawdown
-37.8%
Largest decline past year
52-Week Range
$180-$294
Price range past year
Annual Return
-21.8%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | -2.9% |
| 3m | -9.2% | +15.0% |
| 6m | -18.2% | +5.6% |
| 1y | -21.8% | +19.1% |
| ytd | -18.2% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
Revenue growth remains positive but has shown signs of deceleration; the most recent quarterly revenue was $1.42 billion, representing a year-over-year growth of 10.98%, which is a slowdown from the higher growth rates seen in prior quarters. Segment data shows the core 'Sleep and Respiratory' business generated $1.26 billion, while the 'Residential Care Software' segment contributed $166.87 million, indicating the core hardware business remains the primary growth driver. The company is highly profitable, with net income of $392.59 million in the latest quarter and a robust gross margin of 62.18%. Profitability metrics are strong, with a net margin of 27.59% and an operating margin of 34.97%, reflecting efficient operations and pricing power within its niche. The balance sheet and cash flow position are exceptionally healthy, with a low debt-to-equity ratio of 0.14, a strong current ratio of 3.44, and trailing twelve-month free cash flow of $1.79 billion. This substantial cash generation, coupled with a return on equity of 23.47%, indicates the company can comfortably fund growth, dividends, and share repurchases without relying on external financing, presenting low financial risk.
Quarterly Revenue
$1.4B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Given the company's consistent profitability with net income of $392.59 million, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 27.02x, while the forward PE is notably lower at 15.56x, indicating the market expects significant earnings growth in the coming year. Compared to sector averages, ResMed's trailing PE of 27.02x trades at a premium, which is typical for a market leader with high margins, but the forward multiple suggests this premium may compress if growth expectations are met. Historically, the stock's own PE ratio has fluctuated; the current trailing multiple of 27.02x is above the lower end of its historical range seen in recent quarters but well below the highs above 40x seen in 2021-2022, suggesting the valuation has moderated from peak optimism but is not at bargain levels.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -90x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ResMed's primary financial risk is not solvency but growth sustainability to justify its valuation. The company's revenue growth decelerated to 11% YoY in the latest quarter, and a further slowdown could trigger significant multiple compression from its current trailing P/E of 27x. While the balance sheet is strong (D/E 0.14), the company's premium valuation (PS ratio of 7.36x) makes it sensitive to any earnings miss or guidance reduction. Dependence on the core Sleep & Respiratory segment (~89% of revenue) also presents concentration risk, though recent acquisitions aim to diversify.
Market & Competitive Risks: The stock faces substantial market risk from valuation compression, as its trailing P/E of 27.02x sits at a premium to the sector. With a beta of 0.78, it has been less volatile than the market but has still experienced a max drawdown of -37.76% during this downturn, indicating stock-specific and sector-related selling pressure. Competitive risks are heightened by the potential for market share loss or pricing pressure in its core device business. Furthermore, limited analyst coverage (7 analysts) can lead to exaggerated moves on company-specific news, increasing volatility.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, catalyzed by a material miss on revenue growth (falling below 8%) and margin contraction in the next quarterly report. This could trigger a wave of analyst downgrades from the already mixed sentiment, leading to a re-rating towards the lower end of its historical valuation range. A realistic downside target aligns with the 52-week low of $180.27, representing a potential loss of approximately -4.5% from the current price of $188.63. A breach of this level could see the stock test the $170-$175 range, implying a total downside risk of -10% to -15%.
FAQ
The key risks are, in order of severity: 1) Growth Sustainability: Revenue growth decelerated to 11% YoY; a further slowdown could crush its premium valuation. 2) Technical & Sentiment Risk: The stock is in a severe downtrend, down 25% over the past year, indicating powerful negative momentum that can be self-reinforcing. 3) Competitive/Market Risk: As a market leader, it faces constant pricing and innovation pressure in its core sleep apnea business. 4) Coverage Risk: With only 7 covering analysts, the stock is more vulnerable to volatility from individual rating changes.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $210 and $240 as growth stabilizes around 10%. The Bull Case (30% probability) targets $275-$295 on re-accelerated growth and a sentiment reversal. The Bear Case (20% probability) warns of a drop to $170-$190 if growth deteriorates further. The Base Case is most likely, anchored by the assumption that revenue growth stabilizes near current levels and the forward P/E of ~15.6x provides valuation support, preventing a crash but also limiting a sharp rally without new catalysts.
RMD's valuation is in transition. On a trailing basis, its P/E of 27.02x is at a premium to the sector, suggesting it is still somewhat overvalued relative to peers. However, its forward P/E of 15.56x is much more reasonable and implies the market expects significant earnings growth. Compared to its own history, the valuation has moderated substantially from peaks above 40x. The current price suggests the market is pricing in a fair value for a company with slowing growth but high profitability, making it neither deeply undervalued nor egregiously overvalued.
RMD is a Hold, not a clear Buy at this moment. For value-oriented investors with a long-term horizon, the forward P/E of 15.6x and strong cash flow profile are attractive. However, the severe technical downtrend (-25% Y/Y) and decelerating revenue growth (11% YoY) present significant near-term headwinds. It could be a good buy for those who believe the company's fundamental strengths will ultimately prevail, but only on a scale-in basis or after technical signs of a bottom form. The biggest downside risk is a further growth slowdown triggering more multiple compression.
RMD is far more suitable for a long-term investment horizon of 3-5 years. Its low beta (0.78) and strong dividend (though low yield) support a buy-and-hold approach for investors seeking exposure to the durable sleep apnea market. The current technical turmoil and growth deceleration make it a poor candidate for short-term trading, as the lack of a clear near-term catalyst could lead to continued sideways or negative price action. A minimum holding period of 18-24 months is suggested to allow time for the company's strategic initiatives to bear fruit and for the technical picture to repair.